GRAS in the US (the only place I know of that uses this specific terminology) is reserved for nutritional substances, i.e. they are eaten - taken by mouth. GRAS does not have any application to medical devices.
Nevertheless, your point is otherwise valid as much underlying research on safety, pharmacokinetics, etc. should not need to be reinvented from scratch. The research will, however need to be resubmitted with each new application.
6 months, page-13
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.58 |
Change
-0.060(2.27%) |
Mkt cap ! $1.788B | |||
| Open | High | Low | Value | Volume |
| $2.63 | $2.64 | $2.58 | $715.2K | 273.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 25 | 21711 | $2.58 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.59 | 16340 | 38 |
View Market Depth
| Last trade - 14.17pm 30/09/2024 (20 minute delay) ? |
| PNV (ASX) Chart |